Study #2018-0489
A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients with Bronchiolitis Obliterans syndrome (BOS) after Allogeneic Hematopoietic Cell Transplant (HCT)
MD Anderson Study Status
Not Accepting
Treatment Agent
Itacitinib, Itacitinib Adipate
Description
This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Bronchiolitis Obliterans
Study phase:
Phase I
Physician name:
Amin Alousi
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.